At Veracyte, we are committed to transforming patient care through innovative molecular diagnostics that deliver precise and clinically actionable insights. Founded in 2008, we pioneered the Afirma Genomic Sequencing Classifier technology, which established a new field known as molecular cytology. Our technology enables physicians to make more informed diagnostic and treatment decisions, ultimately improving patient outcomes and reducing unnecessary healthcare costs.
Our origins trace back to the groundbreaking work of Dr. Brett Circe and Dr. Tom Weis, whose scientific vision set the foundation for our mission. We combine cutting-edge genomic science with advanced bioinformatics to provide physicians with accurate diagnostic tools across various medical specialties.
Headquartered in South San Francisco, we are proud to serve the global medical community by translating complex genomic data into clear clinical answers. Our dedicated leadership team, including our co-founder and Executive Chairwoman Bonnie H. Anderson and CEO Marc A. Stapley, drives our growth and innovation forward.
We continuously invest in research and development to expand our portfolio of diagnostic tests, aiming to address unmet clinical needs in oncology, pulmonology, endocrinology, and other fields. Our ultimate goal is to empower healthcare providers with information that enhances patient care pathways, reduces uncertainty, and optimizes treatment strategies.
By focusing on molecular diagnostics, we strive to make a meaningful impact on healthcare systems worldwide, improving quality of life for patients through precision medicine and personalized treatment approaches. Veracyte stands at the forefront of genomic diagnostics, committed to shaping the future of medicine with science, technology, and patient-centric innovation.